What Can the Pharma Industry Learn from Merck’s New Antiviral?

 

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs. For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding. Work on the related compound was active at Emory University as far back as 2004, with millions

With that kind of federal investment, and Operation Warp Speed validating the role of the federal government in supporting critical biomedical development, we wanted to know: can the industry expect any further involvement, financial or regulatory, from the federal government around COVID treatments? Plus, as Operation Warp Speed accelerated the COVID vaccine research timeline, are there more sustainable ways to bring this level of turnaround to other parts of the pharmaceutical pipeline without lags in treatment quality or oversight?

MarketScale sourced Dr. Kishor M. Wasan, Chief Medical and Scientific Officer at Skymount Medical, for his perspective, pulling from his active research around drug production and AI. Scroll down for his various insights!

1. Do the Successes of Operation Warp Speed Validate the Support of the Federal Government?

 

2. How LSU Designed a Model to Speed Up the Evaluation of Drug Candidates

 

3. How the Pharmaceutical Pipeline can Balance Speed and Quality

 

Follow us on social media for the latest updates in B2B!

Image

Latest

visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More
AMAG Technology
AMAG Technology Drives Positive Change, Product Innovation, and Stronger Partnerships with the Customer in Mind
April 2, 2025

At AMAG Technology, customer obsession is at the heart of everything the company does. Customer Relationship Manager Aimee Walsh shares how AMAG embraces positive change, enhances its products, and strengthens partnerships—all with the customer in mind. Her insights reflect AMAG’s ongoing commitment to evolving alongside customer needs and delivering meaningful solutions.

Read More